Bibliographic Details
| Title: |
Darolutamide does not interfere with OATP‐mediated uptake of docetaxel. |
| Authors: |
Buck, Stefan A. J., Talebi, Zahra, Drabison, Thomas, Jin, Yan, Gibson, Alice A., Hu, Peng, de Bruijn, Peter, de Ridder, Corrina M. A., Stuurman, Debra, Hu, Shuiying, van Weerden, Wytske M., Koolen, Stijn L. W., de Wit, Ronald, Sparreboom, Alex, Mathijssen, Ron H. J., Eisenmann, Eric D. |
| Source: |
International Journal of Cancer; Jul2024, Vol. 155 Issue 2, p314-323, 10p |
| Subject Terms: |
DOCETAXEL, ANDROGEN receptors, PROSTATE cancer patients, DRUG interactions |
| Abstract: |
The addition of darolutamide, an androgen receptor signalling inhibitor, to therapy with docetaxel has recently been approved as a strategy to treat metastatic prostate cancer. OATP1B3 is an SLC transporter that is highly expressed in prostate cancer and is responsible for the accumulation of substrates, including docetaxel, into tumours. Given that darolutamide inhibits OATP1B3 in vitro, we sought to characterise the impact of darolutamide on docetaxel pharmacokinetics. We investigated the influence of darolutamide on OATP1B3 transport using in vitro and in vivo models. We assessed the impact of darolutamide on the tumour accumulation of docetaxel in a patient‐derived xenograft (PDX) model and on an OATP1B biomarker in patients. Darolutamide inhibited OATP1B3 in vitro at concentrations higher than the reported Cmax. Consistent with these findings, in vivo studies revealed that darolutamide does not influence the pharmacokinetics of Oatp1b substrates, including docetaxel. Docetaxel accumulation in PDX tumours was not decreased in the presence of darolutamide. Metastatic prostate cancer patients had similar levels of OATP1B biomarkers, regardless of treatment with darolutamide. Consistent with a low potential to inhibit OATP1B3‐mediated transport in vitro, darolutamide does not significantly impede the transport of Oatp1b substrates in vivo or in patients. Our findings support combined treatment with docetaxel and darolutamide, as no OATP1B3 transporter based drug–drug interaction was identified. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
